Skip to main content

Advertisement

SpringerLink
Log in

How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Purpose

Intensive multifactorial risk factor intervention, targeting blood glucose, blood pressure and low-density lipoprotein cholesterol, is central to therapeutic management of type 2 diabetes. This strategy reduces, but does not eliminate the risk for cardiovascular complications, and microvascular complications such as diabetic retinopathy and nephropathy still continue to develop or progress. Fibrates have been shown to be effective in managing mixed dyslipidemia characterized by elevated triglycerides and low high-density lipoprotein cholesterol (HDL-C), typically associated with type 2 diabetes.

Methods

Data were reviewed from the largest fibrate study to date, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study which evaluated the effect of fenofibrate treatment in 9,795 patients with type 2 diabetes (about 80% without prior cardiovascular disease or microvascular complications).

Results

Although FIELD did not show a significant benefit with fenofibrate for major coronary events (the primary outcome), there was significant reduction in total cardiovascular events (relative risk reduction [RRR] 11%, p = 0.035 vs. placebo). The clinical benefits of fenofibrate treatment were greater in patients with marked mixed dyslipidemia (elevated triglycerides ≥200 mg/dL and low plasma levels of HDL-C), features of the metabolic syndrome commonly observed in patients with type 2 diabetes, with a RRR of 27%, p = 0.005. These data are consistent with evidence from other fibrate trials showing increased treatment benefits in patients with metabolic syndrome or type 2 diabetes and mixed dyslipidemia. The FIELD study also provided promising data for microvascular benefits with fenofibrate, specifically on the need for laser treatment for diabetic retinopathy, progression of albuminuria, and prevention of diabetes-related lower-limb amputation.

Conclusions

Adding fenofibrate to primary statin therapy might be a useful strategy to address residual macrovascular and microvascular risk in type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. American Diabetes Association. Standards of medical care in diabetes–2008. Diabetes Care. 2008;31:S12–54.

    Article  Google Scholar 

  2. International Diabetes Federation. Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes 2005. Available at http://www.idf.org. Accessed April 17, 2009.

  3. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.

    Article  PubMed  Google Scholar 

  4. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.

    Article  CAS  PubMed  Google Scholar 

  5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    Article  Google Scholar 

  6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.

    Article  CAS  PubMed  Google Scholar 

  7. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

    Article  Google Scholar 

  8. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.

    Article  CAS  PubMed  Google Scholar 

  9. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.

    CAS  PubMed  Google Scholar 

  10. Assmann G. Dyslipidemia and global cardiovascular risk: clinical issues. Eur Heart J Suppl. 2006;8:f40–6.

    Article  Google Scholar 

  11. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;297:309–16.

    Article  Google Scholar 

  12. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;297:299–308.

    Article  Google Scholar 

  13. Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis. 1991;89:109–16.

    Article  CAS  PubMed  Google Scholar 

  14. Brunzell JD, Davidson M, Furberg CD, American Diabetes Association, American College of Cardiology Foundation, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811–22.

    Article  CAS  PubMed  Google Scholar 

  15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143–421.

    Google Scholar 

  16. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A Scientific Statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114–26.

    Article  PubMed  Google Scholar 

  17. Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70:263–9.

    Article  PubMed  Google Scholar 

  18. Barter PJ, Gotto AM, LaRosa JC, et al. Treating to new targets investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.

    Article  CAS  PubMed  Google Scholar 

  19. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.

    Article  CAS  PubMed  Google Scholar 

  20. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis. 2003;171:1–13.

    Article  CAS  PubMed  Google Scholar 

  21. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart study. Implications for treatment. Circulation. 1992;85:37–45.

    CAS  PubMed  Google Scholar 

  22. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med. 2002;162:2597–604.

    Article  CAS  PubMed  Google Scholar 

  23. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA. 2001;285:1585–91.

    Article  CAS  PubMed  Google Scholar 

  24. The BIP Study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) study. Circulation. 2000;102:21–7.

    Google Scholar 

  25. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154–61.

    Article  CAS  PubMed  Google Scholar 

  26. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–10.

    Article  Google Scholar 

  27. Keech A, Simes RJ, Barter P, The FIELD study investigators, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.

    Article  CAS  PubMed  Google Scholar 

  28. Hunt KJ, Resendez RG, Williams K, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251–7.

    Article  PubMed  Google Scholar 

  29. Scott R, O’Brien R, Fulcher G, et al. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care. 2009;32:493–8.

    Article  CAS  PubMed  Google Scholar 

  30. Keech AC, Mitchell P, Summanen PA, FIELD study investigators, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–97.

    Article  CAS  PubMed  Google Scholar 

  31. ETDRS Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766–85.

    Google Scholar 

  32. ETDRS Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETRDS report number 10. Ophthalmology. 1991;98:786–806.

    Google Scholar 

  33. Simó R, Hernández C. Fenofibrate for diabetic retinopathy. Lancet. 2007;370:1667–8.

    Article  PubMed  Google Scholar 

  34. Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes. 1969;18:285–91.

    CAS  PubMed  Google Scholar 

  35. Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. ETDRS Report 22. Arch Ophthalmol. 1996;114:1079–84.

    CAS  PubMed  Google Scholar 

  36. Ucgun NI, Yildirim Z, Kiliç N, Gürsel E. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann NY Acad Sci. 2007;100:213–7.

    Article  Google Scholar 

  37. Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid-lowering therapy? Eye. 2002;16:689–93.

    Article  CAS  PubMed  Google Scholar 

  38. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910–8.

    Article  PubMed  Google Scholar 

  39. Kim J, Ahn JH, Yu YS, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res. 2007;84:886–93.

    Article  CAS  PubMed  Google Scholar 

  40. Skrha J, Stulc T, Hilgertová J, et al. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol. 2004;493:183–9.

    Article  CAS  PubMed  Google Scholar 

  41. Goetze S, Eilers F, Bungenstock A, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Comm. 2002;293:1431–7.

    Article  CAS  PubMed  Google Scholar 

  42. Demircan N, Safran BG, Soylu M, et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20:1366–9.

    Article  CAS  PubMed  Google Scholar 

  43. Ryan KE, McCance DR, Powell L, et al. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis. 2007;194:e123–30.

    Article  CAS  PubMed  Google Scholar 

  44. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45:485–93.

    Article  CAS  PubMed  Google Scholar 

  45. Rajamani K, Colman PG, Li LP, FIELD study investigators, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373:1780–8.

    Article  CAS  PubMed  Google Scholar 

  46. Fazio S, Linton MF. Fenofibrate and risk of minor amputations in diabetes. Lancet. 2009;373:1740–1.

    Article  PubMed  Google Scholar 

  47. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res. 2008;49:499–509.

    Article  CAS  PubMed  Google Scholar 

  48. Kömüves LG, Hanley K, Lefebvre AM, et al. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol. 2000;115:353–60.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The preparation of this manuscript was assisted by an unrestricted educational grant from ABBOTT Laboratories.

Conflict of interest statement

The author has delivered lectures sponsored by Solvay, Roche, Merck, and Astra Zeneca.

Author information

Authors and Affiliations

  1. Toronto General Hospital, University of Toronto, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada

    George Steiner

Authors
  1. George Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Steiner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steiner, G. How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD. Cardiovasc Drugs Ther 23, 403–408 (2009). https://doi.org/10.1007/s10557-009-6190-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-009-6190-7

Key words

Search

Navigation